A Focus on the First 1,000 Days
Starting at conception, the health of both mother and child are of utmost importance. At Astarte Medical, we view the first 1,000 days as a window of opportunity to deliver solutions that allow hospitals and clinical teams to standardize care protocols and customize treatment plans, at a time that has a profound impact on long-term health.
These first 1,000 days are especially critical for preterm infants, who are facing significant challenges, which include:
Growth
Failure
Allergy, Asthma
and Obesity
Neurodevelopmental
Delays or Disabilities
Our NICUtrition Platform
Core to Astarte Medical is our comprehensive and proprietary dataset, which integrates feeding protocols, microbiome profiles and clinical information. Our NICUtrition® suite of products provides actionable information in real time to hospitals and clinical teams, enabling them to standardize care protocols, and customize treatment plans by quantifying preterm infant gut health.
About Astarte Medical
Led by a distinguished team and world-class advisors in neonatology, nutrition and microbiome, Astarte Medical is the only precision medicine company using software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants.
Featured News
Astarte Medical Appoints Giulia Kennedy to Board of Directors
Experienced investors want to prove that funding advances in women’s health is
‘worth it’
Digital health investments bounced back in Q2 2019 with nearly $2.5B in funding
Events
Astarte will be exhibiting at the show in San Diego, CA.
Astarte will be exhibiting at HLTH 2019 in Las Vegas, NV.
Advancing research, understanding & application.